Lay Press

Who says what’s best?  by Bernadine Healy M.D. US News and World Report. September 11, 2006.
Available at: http://health.usnews.com/usnews/health/articles/060903/11healy.htm
Accessed June 26, 2008.

Summary:
Discusses  EBM’s ideological and political agenda and how it must be separate from its clinical purpose.


Medical journal editors take hard line on drug research.  The Washington Post. September 10, 2004
Available at:  http://www.smh.com.au/articles/2004/09/09/1094530773888.html
Accessed July 5, 2008.

Summary:
Medical Journals set new standards for publishing research


FDA to Leave Antibiotic Ketek on the Market by Joanne Silberner. NPR.  December 16, 2006.
Available at: http://www.npr.org/templates/story/story.php?storyId=6635165
Accessed July 21, 2008

Summary:
Claims the FDA ignored problems with Ketek and the “FDA saw that it needed to align its interests with the company’s, and the company’s interest was ‘get this drug approved.’”


Accusations of Delays in Releasing Drug Results by Alex Berenson. NYTIMES.  April 1, 2008.
Available at: http://www.nytimes.com/2008/04/01/business/01drug.html?pagewanted=print
Accessed July 21, 2008

Summary:
Discusses the controversy of the delayed release of the Enhance trial results for two years and the promotion of Vytorin and Zetia by Merck and Schering-Plough during that time.


Congress Sends Letters to ACC and AHA Over ENHANCE Press Release and Industry Funding by  Michael O’Riordan.  Heartwire — a professional news service of WebMD.
Available at: http://www.medscape.com/viewarticle/569285
Accessed July 21, 2008

Summary:
Mentions how the AHA failed to disclose that it receives $2 million annually from Merck/Schering-Plough, the joint venture that funded the study and currently markets the ezetimibe/simvastatin combination.


Financial ties to industry cloud major depression study; at issue: whether it’s safe for pregnant women to stay on medication; JAMA asks author to explain. By Armstrong D.  Wall St J (East Ed). 2006 Jul 11:A1, A9.
Available at: http://www.healthcoalition.ca/wsj2006.pdf
Accessed August 18, 2008

Summary:
The authors of a depression study failed to disclose relationships with pharmaceutical companies.  Their results were beneficial to the companies selling antidepressants.


Rent-a-Researcher.  Did a British university sell out to Procter & Gamble? By Jennifer Washburn.  Slate. December. 22, 2005.
Available at: http://www.slate.com/id/2133061/
Accessed August 18, 2008

Summary:
Sheffield University accused of allowing industry interference with academic research.


Guinea-pigging: Healthy human subjects for drug safety trials are in demand. but is it a living? By Elliott, C. (2008).  New Yorker (New York, N.Y.: 1925), , 36-41.

Available at http://www.newyorker.com/reporting/2008/01/07/080107fa_fact_elliott

PMID: 18265451

Summary:
Lay Press article in the New Yorker discussing the impact of CROs and ethical considerations that need to be made.


Report Assails F.D.A. Oversight of Clinical Trials.  By GARDINER HARRIS.  New York Times. September 28, 2007.

Available at: http://www.nytimes.com/2007/09/28/health/policy/28fda.html?_
r=3&scp=1&sq=assails%20FDA%20oversight%20of%20clinical%20trials&st=cse&oref=slogin&oref=slogin&oref=slogin

Accessed August 18, 2008